↓ Skip to main content

New directions in the management of advanced pancreatic cancer: a review

Overview of attention for article published in Anti-Cancer Drugs, June 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
1 X user
patent
2 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
37 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
New directions in the management of advanced pancreatic cancer: a review
Published in
Anti-Cancer Drugs, June 2008
DOI 10.1097/cad.0b013e3282fc9d11
Pubmed ID
Authors

Caio M Rocha-Lima

Abstract

Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and topoisomerase I inhibitors) or targeted therapies (farnesyl transferase inhibitors, metalloproteinase inhibitors, cetuximab and bevacizumab) to gemcitabine has failed to improve outcome. The combination of gemcitabine and erlotinib, a small-molecule tyrosine kinase inhibitor of the human epidermal growth factor receptor, was recently approved by the US/European authorities for use in advanced disease. In a phase III trial, the combination demonstrated a significant improvement in overall survival compared with gemcitabine monotherapy. Positive efficacy results have also been observed in a phase III trial, favoring the addition of capecitabine to gemcitabine compared with gemcitabine alone. This review focuses on the recent developments in systemic treatment, and discusses how novel agents might be incorporated into future treatment strategies for pancreatic cancer.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
China 1 2%
Unknown 42 93%

Demographic breakdown

Readers by professional status Count As %
Other 6 13%
Student > Ph. D. Student 6 13%
Student > Bachelor 5 11%
Researcher 3 7%
Professor 3 7%
Other 10 22%
Unknown 12 27%
Readers by discipline Count As %
Medicine and Dentistry 20 44%
Agricultural and Biological Sciences 5 11%
Nursing and Health Professions 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Unspecified 1 2%
Other 4 9%
Unknown 13 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2016.
All research outputs
#5,140,637
of 25,373,627 outputs
Outputs from Anti-Cancer Drugs
#106
of 1,835 outputs
Outputs of similar age
#18,099
of 97,663 outputs
Outputs of similar age from Anti-Cancer Drugs
#1
of 10 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,835 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,663 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them